Ora, Inc. Featured in NHS 75: Celebrating 75 Years of the National Health Service
Ora, Inc., the world’s leading Clinical Research Organisation (CRO) for ophthalmology pharmaceutical and device development, announced today its inclusion in the NHS 75: Celebrating 75 Years of the National Health Service (NHS) book, launching today at the Palace of Westminster.
To commemorate the 75th anniversary of the NHS, a beautifully presented hardback book has been produced in partnership by the History of Parliament Trust and publisher St James’s House. Researched and written by a select team of academics and industry experts, this fully illustrated publication explores the origins, history and impact of the NHS and the people and policies that helped to evolve this service over time.
“It's an honour to be a part of this milestone event for the NHS,” said Stuart Abelson, CEO, Ora, Inc. “The National Health Service has delivered and innovated world leading healthcare throughout England for 75 years. Ora is passionate about supporting innovation in eyecare by delivering the highest quality clinical research programs through a people-first approach and cutting-edge processes and technology like the Ora EyeCup©. Together, these accelerate the development and approval of new drugs and devices for patients suffering from vision related illness. We are also deeply committed to greater access to clinical research as a care option and support the National Health Service and their mission to provide outstanding healthcare for the people of England.”
Founded in 1948, the NHS was the first universal health system able to successfully evolve and adapt to meet the needs of new generations. Today this service sees over a million people daily in England.
Richard Freed, founder of St James’s House, said: “We are delighted to be launching this fantastic book heralding all that is great about the National Health Service. The 75th anniversary offers the perfect opportunity to reflect on the past, present, and future of the NHS.”
Notes to editors:
NHS 75: Celebrating 75 Years of the National Health Service is available to order at www.stjamess.org.
About Ora Clinical
Ora is the world's leading full-service ophthalmic drug and device development firm with offices in North America, South America, Europe, Australia, and Asia. For over 45 years, we have proudly helped our clients earn more than 80 product approvals. We support a wide array of organisations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora's pre-clinical and clinical models, unique methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world's most extensive and experienced team of ophthalmic experts, R&D professionals, and management executives to maximise the value of new product initiatives. For more information, please visit www.oraclinical.com, like us on Facebook, and follow us on LinkedIn.
Ora® and Ora Logo are registered trademarks of Ora, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230906680228/en/
Contact information
Anne Marie Jedraszczak
ajedraszczak@oraclinical.com
(978) 685-8900
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Announces Third-Quarter 2023 Results Conference Call22.9.2023 20:00:00 EEST | Press release
SLB (NYSE:SLB) will hold a conference call on October 20, 2023 to discuss the results for the third quarter ending September 30, 2023. The conference call is scheduled to begin at 9:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 8858313. A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until November 20, 2023, and can be accessed by dialing +1 (866) 207-1041 within North America or +1 (402) 970-0847 outsid
Energy Dome's CO2 Battery™ to Revolutionize U.S. Energy Landscape With First Installation Slated for 202622.9.2023 18:45:00 EEST | Press release
A groundbreaking development in sustainable energy storage is on the horizon for Columbia County, Wisconsin, U.S., spearheaded by Alliant Energy in collaboration with Energy Dome and other key stakeholders. Alliant Energy has just announced its selection to receive a federal grant of up to approximately $30 million from the U.S. Department of Energy's Office of Clean Energy Demonstrations (OCED) for the pioneering Columbia Energy Storage Project, a proposed 200-megawatt hour energy storage system, based on Energy Dome’s signature technology: the CO2 Battery™. This visionary battery system, aptly named the “Columbia Energy Storage Project”, is poised to be a trailblazer in the United States, marking a pivotal stride towards a more sustainable, reliable, and cost-effective energy future. Claudio Spadacini, CEO of Energy Dome, declared: “I’m honored to be part of this remarkable journey alongside Alliant Energy. The Columbia Energy Storage Project marks the genesis of a new era, where the
Settlement Administrator Angeion Group Announces Proposed Settlement In U.S. Dollar LIBOR-Based Instrument Class Action22.9.2023 16:00:00 EEST | Press release
There are lawsuits impacting individuals and institutions that entered into over-the-counter financial derivative and non-derivative instruments directly with 17 banks and that received payments tied to U.S. Dollar LIBOR. A Settlement totaling $101 million has been reached with Coöperatieve Rabobank U.A. (“Rabobank”), Lloyds Banking Group plc, Lloyds Bank plc, HBOS plc, and Bank of Scotland plc (together, “Lloyds”), Royal Bank of Canada (“RBC”), and Portigon AG and Westdeutsche Immobilien Servicing AG (together “Portigon”). Earlier settlements totaling $680 million were reached with Barclays, Citibank, Deutsche Bank, HSBC, MUFG, Norinchukin, and SocGen bringing the total settlement amount to $781 million. The remaining Non-Settling Defendants include Bank of America, Credit Suisse, JPMorgan Chase, Royal Bank of Scotland, and UBS. What does the Settlement provide? The Settlement will create a Settlement Fund totaling $101 million that will be used to pay eligible Class Members who submi
Kenvue to Announce Third Quarter 2023 Results on October 26, 202322.9.2023 13:30:00 EEST | Press release
Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the third quarter ending October 1, 2023, before market open on October 26, 2023. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its third quarter results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or 201-689-8779 from international locations. A live webcast of the conference call will be available at https://investors.kenvue.com. A replay will be available approximately two hours after the live event. About Kenvue Kenvue is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand Adhesive Bandages, Johnson’s®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe in the extraordinary
OS Achieves 800-Puff Milestone with FEELM Max Technology22.9.2023 12:34:00 EEST | Press release
A significant mark in the vaping industry was set when OS Vape, a pioneering disposable product series from OS, showcased its dynamic range at the InterTabac from September 14th to 16th in Germany. Recognized as a leading brand in Germany's shisha product market, OS boasts an extensive local network of channels. Drawing upon this rich resource base, OS's foray into the disposable e-cigarette domain promises consumers enhanced puff counts, cost-efficiency, and unparalleled vapor consistency. As revealed by Future Marketing Insights, Europe's disposable market witnessed a substantial surge, accounting for a 32.3% revenue share in 2022. This robust growth underscores the escalating consumer preference for hassle-free, smokeless alternatives that eliminate the need for recharges or refills. The evolution of the disposable sector brings heightened convenience and a broader array of choices for consumers. Capitalizing on this trend, OS, through its innovative product series and leveraging it
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom